DAMORA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
DAMORA THERAPEUTICS, INC. (DMRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 4.00%, a 11.11% decline year-over-year.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.50%, a 15.38% increase year-over-year.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 3.90%, a 2.63% increase year-over-year.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.80%, a 153.33% increase year-over-year.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.00%, a 5.26% increase from fiscal 2023.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.80%, a 123.53% increase from fiscal 2022.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.70%, a 142.86% increase from fiscal 2021.
- DAMORA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.70%, a 75.00% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 4.00% 10-Q · filed 2026-08-10 | ||||
| 2026-03-31 | 4.00% 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | 4.50% 10-Q · filed 2026-05-12 | 3.90% 10-K · filed 2026-03-19 | |||
| 2025-09-30 | 4.40% 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | 4.40% 10-Q · filed 2026-08-10 | ||||
| 2025-03-31 | 4.50% 10-Q · filed 2025-05-08 | ||||
| 2024-12-31 | 4.00% 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | 4.20% 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | 4.20% 10-Q · filed 2025-08-05 | ||||
| 2024-03-31 | 3.90% 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | 3.80% 10-K · filed 2025-03-19 | ||||
| 2023-09-30 | 3.80% 10-Q · filed 2024-11-01 | ||||
| 2023-06-30 | 3.80% 10-Q · filed 2024-08-12 | ||||
| 2023-03-31 | 3.80% 10-Q · filed 2024-04-29 | ||||
| 2022-12-31 | 1.70% 10-K · filed 2024-03-08 | ||||
| 2022-09-30 | 1.70% 10-Q · filed 2023-11-06 | ||||
| 2022-06-30 | 1.70% 10-Q · filed 2023-07-31 | ||||
| 2022-03-31 | 1.50% 10-Q · filed 2023-04-28 | ||||
| 2021-12-31 | 0.70% 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | 0.70% 10-Q · filed 2022-11-08 | ||||
| 2021-06-30 | 0.70% 10-Q · filed 2022-07-29 | ||||
| 2021-03-31 | 0.50% 10-Q · filed 2022-04-29 | ||||
| 2020-12-31 | 0.40% 10-K · filed 2022-02-17 | ||||
| 2020-09-30 | 0.40% 10-Q · filed 2021-11-04 | ||||
| 2020-06-30 | 0.40% 10-Q · filed 2021-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |